A Phase 2b Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Trial Profile

A Phase 2b Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2018

At a glance

  • Drugs Avacincaptad pegol (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors OphthoTech Corporation
  • Most Recent Events

    • 01 Aug 2018 According to an OphthoTech Corporation media release, the company expects to complete in the third quarter 2018 with initial top-line data expected to be available during the second half of 2019.
    • 08 Jun 2018 Planned number of patients changed to 277.
    • 27 Feb 2018 According to an OphthoTech Corporation media release, results from this study were presented at the 41st Annual Macula Society Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top